Citius Pharmaceuticals Newsroom

Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating

Futu NewsNov 28 00:32 · Ratings

Promising Outlook for Citius Pharmaceuticals: Buy Rating Affirmed Amid Product Potential and Strategic Developments

TipRanksNov 28 00:25 · Ratings

Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

BenzingaNov 27 17:52

When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?

Simply Wall StNov 26 21:33

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval

PR NewswireNov 25 21:03

Citius Pharmaceuticals To Carry Out 1-for-25 Reverse Stock Split On November 26th, 2024

November 22nd (Eastern Time) - $Citius Pharmaceuticals(CTXR.US)$ is about to implement a 1-for-25 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from

Futu NewsNov 23 08:40

D. Boral Capital Downgrades Citius Pharmaceuticals(CTXR.US) to Hold Rating

Futu NewsNov 23 05:32 · Ratings

Citius Pharmaceuticals Cut to Hold From Buy by D. Boral Capital

Dow JonesNov 23 05:28 · Ratings

Sector Update: Health Care Stocks Rise Friday Afternoon

MT NewswiresNov 23 02:57

Express News | Citius Pharmaceuticals Inc - Reverse Stock Split Effective at 5:00 PM Et on Nov 25, 2024

BreakingsNov 22 22:00

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split >CTXR

Dow JonesNov 22 22:00

Citius Pharmaceuticals Entered Into Definitive Agreements For The Purchase Of An Aggregate Of 12M Shares Of Its Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 12M Shares Of Its Common Stock, At A Purchase Price Of $0.25 Per...

BenzingaNov 16 02:32

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

PR NewswireNov 16 02:30

Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 12 23:31 · Ratings

Citius Pharmaceuticals' Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating

TipRanksNov 12 23:25 · Ratings

H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 12 21:33 · Ratings

Buy Rating for Citius Pharmaceuticals: Promising Clinical Results and Strong Financial Outlook

TipRanksNov 12 20:45 · Ratings

Citius Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow JonesNov 12 20:44 · Ratings

D. Boral Capital Maintains Buy on Citius Pharma, Maintains $6 Price Target

BenzingaNov 12 06:20 · Ratings

Citius Shares Jump After Reporting Positive Results From Early Study of Potential Cancer Treatment

MT NewswiresNov 12 02:27